Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 20, 2021

High-Dose Cytarabine-Based Regimens vs Liposomal Daunorubicin and Cytarabine in Secondary AML

Leukemia and Lymphoma


Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia and Lymphoma
Multicenter Comparison of High-Dose Cytarabine-Based Regimens Versus Liposomal Daunorubicin and Cytarabine (CPX-351) in Patients With Secondary Acute Myeloid Leukemia
Leukemia and Lymphoma 2021 Apr 08;[EPub Ahead of Print], LL Benitez, AJ Perissinotti, CR Rausch, J Klaus, SM Clark, M Filtz, K Ratermann, C Treptow, S Griffin, M Olson, M Crain, T Kadia, K Pettit, PW Burke, DL Bixby, BL Marini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading